PTC director Alethia Young steps down and stays on as an advisor

On June 8, 2026, Alethia Young, a member of the board of directors of PTC Therapeutics, Inc., notified the company that she was resigning from the board, effective the same day. The company disclosed the change in a Form 8-K signed on June 9, 2026 by Chief Financial Officer Pierre Gravier.

Reason for the resignation

According to the filing, Ms. Young said her decision was based on her need to focus on commitments to her other work activities. The filing states that the resignation was not due to any disagreement with the company. That is the company's statement and the filing adds no detail, and she stays on as a paid adviser.

The consulting agreement

The company and Ms. Young entered into a consulting agreement effective June 8, 2026. Under it, she will remain as an advisor to PTC, with a term continuing through June 8, 2027. She will receive a monthly consulting fee of $4,166.67. The agreement is filed as Exhibit 10.1 to the 8-K, and the description in the filing is qualified by the full text of that exhibit.

The 8-K is limited to the resignation and the consulting arrangement. It does not describe any change to the board's committee assignments, and it does not name a successor or say whether the board will fill the seat.

The company

PTC describes itself in its annual report as a global biopharmaceutical company dedicated to the discovery, development and commercialization of medicines for children and adults living with rare disorders. Its pipeline is focused on new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism.

The company's commercial products include Sephience (sepiapterin), which is approved for phenylketonuria in the United States, the European Economic Area, Japan and additional geographies. PTC also sells Translarna (ataluren) and Emflaza (deflazacort) for Duchenne muscular dystrophy, and it markets Kebilidi, the brand name of eladocagene exuparvovec-tneq, for AADC deficiency in the United States. Evrysdi (risdiplam) for spinal muscular atrophy is developed with Roche and the Spinal Muscular Atrophy Foundation.

In the annual report, the company also describes votoplam, a splicing program for Huntington's disease. Novartis has taken over responsibility for further development of that program, and PTC continues to collaborate with Novartis on next steps.

Financial position

The financial figures in this story come from the annual report filed on February 19, 2026, the most recent annual report available at the date of this story. PTC reported research and development expense of $455.2 million for 2025, compared with $534.5 million for 2024. It reported net income of $682.6 million for 2025, compared with a net loss of $363.3 million for 2024.

Cash from operations was $711.2 million in 2025, compared with negative $107.7 million in 2024. Year-end 2024 cash and cash equivalents were $779.7 million, with short-term investments of $360.0 million. Net income in 2025 followed a net loss the year before, so the profit is recent.

What comes next

The filing sets out the consulting term, which runs through June 8, 2027, and the monthly fee. It does not give a date for any board appointment.

The annual report also sets out the company's strategy, which it describes as leveraging its scientific expertise and global commercial infrastructure to optimize value for patients and other stakeholders. The risks include Translarna: its conditional approval in the European Economic Area was the subject of a March 2025 negative opinion from the Committee for Medicinal Products for Human Use, and the report says individual countries in the European Union can still allow continued commercial use of the product. Under a collaboration with a subsidiary of Ionis Pharmaceuticals, PTC holds the rights to Tegsedi and Waylivra for rare diseases in Latin America and the Caribbean.

Report an error

Companies in this story

PTCTPTC Therapeutics, Inc.NASDAQ · United StatesOpen the starter desk